Oculis (OCS)

Executive Summary

Oculis is a Swiss clinical-stage biopharmaceutical company focused on developing innovative, non-invasive treatments for ophthalmic and neuro-ophthalmic diseases. Founded in 2014 and headquartered in Lausanne, the company leverages small molecules and biologic candidates to address significant unmet medical needs. Oculis's pipeline targets conditions such as dry eye disease, glaucoma, and neuro-ophthalmic disorders, with an emphasis on patient-friendly topical formulations. The company is publicly traded under the ticker OCS and has an estimated valuation of approximately $676 million. Oculis is positioned to advance its lead candidates through clinical trials, with potential for value inflection from key data readouts and regulatory interactions in the near term.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b/3 trial results for lead candidate in dry eye disease60% success
• TBDInitiation of Phase 2 trial for neuro-ophthalmic candidate70% success
• Q4 2026Potential strategic partnership for non-invasive delivery platform50% success